NASDAQ: LTGOLatigo Biotherapeutics Inc Stock
$13.11+0.18 (+1.39%)
Updated Nov 13, 2026
LTGO Price
$13.11
Fair Value Price
N/A
Market Cap
$869.18M
52 Week Low
$10.24
52 Week High
$25.93
P/E
N/A
P/B
2.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
N/A
Beta
2.13
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LTGO Overview
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LTGO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LTGO
Ranked#210 of 450
Ranked#210 of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.66 | A | |
| $955.47 | A | |
| $11.62 | A |
Be the first to know about important LTGO news, forecast changes, insider trades & much more!
LTGO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LTGO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LTGO is good value based on its book value relative to its share price (2.21x), compared to the US Biotechnology industry average (5.14x)
P/B vs Industry Valuation
LTGO's short-term assets ($406.44M) exceed its short-term liabilities ($13.96M)
Short-term Liabilities Financials
LTGO's short-term assets ($406.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more LTGO due diligence checks available for Premium users.
Valuation
LTGO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.21x
Industry
5.14x
LTGO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LTGO's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.9M
Profit Margin
0%
Assets to liabilities
Assets
$408.5M
Liabilities
$14.5M
Debt to equity
0.04
LTGO's short-term assets ($406.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LTGO's short-term assets ($406.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LTGO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.5M
Investing
-$36.0k
Financing
$365.8M
LTGO vs Biotech Stocks
Latigo Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.